Investment in neglected diseases has saved 8 million lives, with 32 million more savable soon.

The claim is about investment in neglected diseases, as reported in a source available by June 2024 (likely a Copenhagen Consensus or similar cost-benefit study). True: credible estimates attribute about 8 million lives saved to such investment and project about 32 million more savable in the near term. These are rough figures, so values within about ±15% count. Mostly true: both figures are right in magnitude but differ somewhat (within about ±30%), or the time frame is slightly misstated. Mixed: one figure matches and the other does not. Mostly false: the figures come from a real source but are misattributed (e.g. to a different intervention category) or substantially distorted. False: no credible estimate is close, or the evidence contradicts the figures.

Set before the research began.

1. E1 Neglected disease investment saved 8 million lives since 2000 Fix The News · 4 June 2024

   “This has resulted in 183 new products, which have saved 8 million lives since 2000 and reduced deaths by more than 30%. With continued scale-up and introduction, more than 32 million additional lives could be saved by 2040.”

2. E2 Case for investment in neglected tropical diseases Journal of Lymphoedema (comment by Josh Ruxin), hosted on woundsinternational.com · 2009

   “In the past seven years, the Global Programme saved an astonishing 32 million disability adjusted life years (DALYs)”

E1 is an independent report published on 2024-06-04, before the claim date. It says investment in neglected-disease R&D produced 183 new products that "have saved 8 million lives since 2000," and that "more than 32 million additional lives could be saved by 2040." Both figures match the claim exactly. The claim's word "soon" is a loose way to describe a projection running to 2040, but the figures and what they are credited to match the source. E2 counts DALYs for a different programme and has no bearing on this claim.